MiR-205 as a promising biomarker in the diagnosis and prognosis of lung cancer.
MiR-205 as a promising biomarker in the diagnosis and prognosis of lung cancer.
复制标题
MiR-205 作为肺癌诊断和预后中有前景的生物标志物
DOI：
10.18632/oncotarget.20262
复制
发表时间：
2017-11-03
期刊：
影响因子：
--
通讯作者：
Wang PY
中科院分区：
文献类型：
--
作者：
Li JH;Sun SS;Li N;Lv P;Xie SY;Wang PY
MicroRNA-205（miR-205）是一种新的肺癌诊断和预后的生物标志物，但在已发表的文献中，其结果并不一致。这项荟萃分析旨在研究miR-205在肺癌患者中的诊断和预后作用。共纳入16篇符合条件的文献，其中10篇研究miR-205的诊断价值，5篇研究其预后价值，1篇同时研究其诊断和预后价值。对于诊断性荟萃分析，肺癌患者miR-205的合并敏感性、特异性、阳性似然比、阴性似然比、诊断优势比和总曲线下面积为0.88（95% CI = 0.78 - 0.94），0.78（95% CI = 0.66 - 0.86），4.00（95% CI = 2.47 - 6.49），0.16（95%CI = 0.08 - 0.30）、25.86（95%CI = 9.29 - 71.95）和0.90（95%CI = 0.87 - 0.92），表明miR-205是用于诊断肺癌的有用生物标志物。亚组分析进一步证明，与血液样品相比，miR-205在组织样品的检测中具有优异的总体准确性。对于预后荟萃分析，无病生存期和无复发生存期分析的汇总结果显示，miR-205水平升高对肺癌患者的预后具有保护作用（汇总HR = 0.86，95%CI：0.78-0.96，z = 2.83，P = 0.005）。总之，miR-205可能是一种有前途的检测生物标志物，预测肺癌患者的复发。
MicroRNA-205 (miR-205) was revealed as a novel diagnostic and prognostic biomarker for lung cancer, but the results in the published papers were inconsistent. This meta-analysis aimed to investigate the diagnostic and prognostic roles of miR-205 in patients with lung cancer. Totally, 16 eligible articles were included, among which 10 articles investigated the diagnostic value of miR-205, 5 articles examined its prognostic values, and 1 article studied both diagnostic and prognostic values. For the diagnostic meta-analysis, the pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, diagnostic odds ratio, and the overall area under the curve of miR-205 for patients with lung cancer were 0.88 (95% CI = 0.78 – 0.94), 0.78 (95% CI = 0.66 – 0.86), 4.00 (95% CI = 2.47 – 6.49), 0.16 (95% CI = 0.08 – 0.30), 25.86 (95% CI = 9.29 – 71.95), and 0.90 (95% CI = 0.87 – 0.92), respectively, indicating that miR-205 is a useful biomarker for diagnostic of lung cancer. The subgroup analysis further demonstrated that miR-205 had an excellent overall accuracy for detection with tissue samples compare with blood samples. For the prognostic meta-analysis, the pooled outcome of the disease-free survival and recurrence-free survival analyses revealed that increased miR-205 levels had a protective role in the prognosis of patients with lung cancer (pooled HR = 0.86, 95% CI: 0.78-0.96, z = 2.83, P = 0.005). In conclusion, miR-205 may be a promising biomarker for detection, predicting the recurrence of patients with lung cancer.